NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-130-2016-0-EP-03 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT EP National Stage 17714118.1 Issued
NCI E-130-2016-0-DE-05 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT DE EP 17714118.1 Issued
NCI E-130-2016-0-FR-06 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT FR EP 17714118.1 Issued
NCI E-130-2016-0-GB-07 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT GB EP 17714118.1 Issued
NIAID E-242-2014-0-US-04 A Monoclonal Antibody Against The N-terminal Portion Of The Circumsporozoite Protein Of Plasmodium Falciparum US CON 16/133,143 10501534 Issued PDF
NINDS E-143-2002-1-US-78 METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS US CON 16/132,852 Abandoned
NCI E-237-2017-2-CN-05 T CELL RECEPTORS RECOGNIZING MUTATED P53 CN National Stage 201880074539.8 Pending
NCI E-237-2017-1-EP-06 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION EP National Stage 18782605.2 Pending
NCI E-237-2017-2-EP-08 T CELL RECEPTORS RECOGNIZING MUTATED P53 EP National Stage 18780006.5 Pending
NCI E-237-2017-1-CN-05 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION CN National Stage 201880063656.4 Pending
NCI E-237-2017-2-CR-06 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR National Stage 2020-0170 Pending
NCI E-237-2017-1-CA-04 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION CA National Stage 3080274 Pending
NCI E-237-2017-2-CA-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 CA National Stage 3077024 Pending
NCI E-237-2017-1-SG-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION SG National Stage 11202002635R Abandoned
NCI E-237-2017-2-SG-15 T CELL RECEPTORS RECOGNIZING MUTATED P53 SG National Stage 11202002636P Pending
NCI E-237-2017-2-KR-12 T CELL RECEPTORS RECOGNIZING MUTATED P53 KR National Stage 2020-7012344 Pending
NCI E-237-2017-1-KR-09 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION KR National Stage 2020-7012343 Pending
NCI E-237-2017-1-PCT-02 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION PCT PCT PCT/US2018/051280 Expired
NCI E-237-2017-2-PCT-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 PCT PCT COMB PCT/US2018/051285 Expired
NCATS E-018-2016-0-US-15 Antifungal Compound Process US DIV 16/132,973 Abandoned
NCI E-237-2017-2-MX-13 T CELL RECEPTORS RECOGNIZING MUTATED P53 MX National Stage MX/a/2020/003504 Pending
NCI E-237-2017-2-NZ-14 T CELL RECEPTORS RECOGNIZING MUTATED P53 NZ National Stage 763023 Pending
NCI E-237-2017-2-IN-10 T CELL RECEPTORS RECOGNIZING MUTATED P53 IN National Stage 202047013911 Pending
NCI E-237-2017-1-IL-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION IL National Stage 273516 Pending
NCI E-237-2017-2-IL-09 T CELL RECEPTORS RECOGNIZING MUTATED P53 IL National Stage 273515 Pending
NCI E-237-2017-2-BR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 BR National Stage BR112020006012-7 Pending
NCI E-237-2017-1-AU-03 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION AU National Stage 2018342245 Pending
NCI E-237-2017-2-AU-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 AU National Stage 2018342246 Pending
NCI E-013-2018-0-US-03 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development US ORD 16/132,064 10501539 Issued PDF
NCI E-013-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19 IMMUNOTHERAPY PCT PCT PCT/US2018/051167 Expired
NCI E-013-2018-0-CN-06 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CN National Stage 201880074006.X Pending
NCI E-013-2018-0-CA-05 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CA National Stage 3075915 Pending
NCI E-013-2018-0-JP-08 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development JP National Stage 2020-515262 Pending
NCI E-013-2018-0-JP-09 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development JP National Stage 2022-031887 Pending
NCI E-205-2016-0-US-05 NANOPARTICLE TO TARGET CANCER US National Stage 16/084,942 11246881 Issued PDF
NIAID E-118-2016-0-NZ-13 Live Attenuated Zika Virus Vaccine NZ National Stage 746349 Abandoned
NIAID E-118-2016-0-AU-03 Live Attenuated Zika Virus Vaccine AU National Stage 2017230112 Abandoned
NIA E-013-2010-0-US-15 THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS US CON 16/129,470 10617654 Issued PDF
NIA E-139-2012-2-US-13 (R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas US CON 16/129,569 10485771 Issued PDF
NCI E-078-2016-0-EP-04 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF EP National Stage 17706653.7 Abandoned
NIDA E-053-2016-1-US-04 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders US National Stage 16/084,093 11299476 Issued PDF
NIDA E-053-2016-1-EP-03 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP National Stage 17711971.6 Issued
NIDA E-053-2016-1-CH-09 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CH EP 17711971.6 Issued
NIDA E-053-2016-1-GB-16 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GB EP 17711971.6 Issued
NIDA E-053-2016-1-TR-31 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders TR EP 17711971.6 Issued
NIDA E-053-2016-1-PT-25 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PT EP 17711971.6 Issued
NIDA E-053-2016-1-RS-27 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RS EP 17711971.6 Issued
NIDA E-053-2016-1-RO-26 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RO EP 17711971.6 Issued
NIDA E-053-2016-1-SE-28 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SE EP 17711971.6 Issued
NIDA E-053-2016-1-PL-24 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PL EP 17711971.6 Issued